IL-17A Inhibitors Restore Intestinal/Skin Microbiota Homeostasis and Altered Microbiota Function in Psoriasis

According to a recent study published in Frontiers in Immunology, IL-17A inhibitors help to restore microbiota homeostasis and metabolic pathways. Additionally, they help reduce pro-inflammatory cytokine expression, and alleviate symptoms in patients with psoriasis.

Researchers aimed to investigate the association between psoriasis and alterations in gut/skin microbiota, as well as the effects of anti-IL17 therapy on gut microbiota in patients with psoriasis. In a case-control study involving patients with psoriasis and healthy controls, gut microbiota dysbiosis was observed in patients with psoriasis, characterized by decreased Bacteroidota and increased Firmicutes and Actinobacteriota. Notably, enrichment of Escherichia-Shigella was associated with reduced serum levels of total bile acid and markers in apoptotic pathways.

Following treatment with IL-17A inhibitors, longitudinal studies revealed a trend toward normalization of the gut microbiome and modulation of apoptosis-related metabolic pathways in patients with psoriasis. Additionally, mouse models corroborated dysregulation of the skin microbiota in psoriasis, characterized by Staphylococcus colonization.

“The psoriatic gut/skin microbiota exhibits loss of community stability and pathogen enrichment,” the authors concluded.

Reference
Zhao H, Shang L, Zhang Y, et al. IL-17A inhibitors alleviate psoriasis with concomitant restoration of intestinal/skin microbiota homeostasis and altered microbiota function. Front Immunol. 2024;15:1344963. doi:10.3389/fimmu.2024.1344963